Pencil Banner October 16 2023

Elevar Therapeutics and Jiangsu Hengrui Pharma announce global commercialization licensing agreement for camrelizumab in combination with rivoceranib for hepatocellular carcinoma LEARN MORE HERE

November 2020

SALT LAKE CITY, USA., November 19, 2020 -- Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced new clinical results from its Phase 1 study

Read more

SALT LAKE CITY, USA., Nov. 17, 2020 – Elevar Therapeutics, Inc. (“Elevar”), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the Company met its initial 55 patient enrollment target

Read more